US2007049549A1PendingUtilityA1

Methods of treating cancer using il-21

65
Assignee: ZYMOGENETICS INCPriority: Jun 7, 2002Filed: Oct 11, 2006Published: Mar 1, 2007
Est. expiryJun 7, 2022(expired)· nominal 20-yr term from priority
A61P 9/00A61P 37/04A61P 35/04A61P 37/02A61P 33/02A61P 31/16A61P 31/04A61P 31/14A61P 35/02A61P 31/00A61P 31/22A61P 31/18A61P 31/06A61P 31/12A61P 25/00A61P 31/10A61P 35/00A61P 31/20A61P 19/02A61P 1/04A61P 1/00A61P 1/16A61P 11/00A61K 38/2026C07K 16/2878C07K 2317/73A61K 38/20A61K 38/193C07K 14/54A61K 45/06A61K 38/2086A61K 38/2013Y02A50/30
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.

Claims

exact text as granted — not AI-modified
1 . A method of tumor vaccination comprising administering to a subject in need thereof an IL-21 polypeptide comprising residues 32 (Gln) to 162 (Ser) of SEQ ID NO:2 in combination with a tumor antigen expressed from injected DNA from breast cancer.  
     
     
         2 . The method according to  claim 1 , wherein the polypeptide has been shown to not cause proliferation of isolated cancer cells prior to administration to the subject.  
     
     
         3 . The method of  claim 1 , wherein there is a tumor response.  
     
     
         4 . The method of  claim 3 , wherein a tumor response is measured as complete response, partial response or reduction in time to progression.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.